The high LGR5 expression levels specific to certain malignancies, rapid internalisation kinetics of α-LGR5 and LGR5 trafficking to the lysosome raised the intriguing prospect of targeting cancers using α-LGR5-based antibody-drug conjugates (ADCs). The gene discussed is LGR5; the disease is cancer.